<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412020001000686</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i10.3357</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Eosinofilia en sangre y cáncer de ovario: estudio fase I de pruebas diagnósticas]]></article-title>
<article-title xml:lang="en"><![CDATA[Blood eosinophilia and ovarian cancer: Phase I study of diagnostic tests]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Álvarez-Sánchez]]></surname>
<given-names><![CDATA[Juan Gabriel]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Opina-Pérez]]></surname>
<given-names><![CDATA[Ana Teresa]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Universidad de Antioquia  ]]></institution>
<addr-line><![CDATA[Medellín Antioquia]]></addr-line>
<country>Colombia</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2020</year>
</pub-date>
<volume>88</volume>
<numero>10</numero>
<fpage>686</fpage>
<lpage>691</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412020001000686&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412020001000686&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412020001000686&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen:  OBJETIVO: Identificar la posible asociación entre la eosinofilia en sangre y el diagnóstico de cáncer de ovario.  MATERIALES Y MÉTODOS:  Estudio transversal, retrospectivo, fase 1 de desarrollo de una prueba diagnóstica. Los datos se recolectaron de las historias clínicas de pacientes atendidas en el Hospital San Vicente Fundación con diagnóstico de tumor de ovario entre el 1 de enero de 2011 y el 1 de enero de 2016. Se incluyeron todas las pacientes con impresión diagnóstica de tumor de ovario con, al menos, un hemoleucograma al ingreso. Se excluyeron las historias clínicas de pacientes con antecedente de atopia que estuvieran cursando en el momento con parasitosis o tuvieran diagnóstico de linfoma de Hodgkin, cáncer colorrectal, mama y cuello del útero. Variables de estudio: edad, cantidad absoluta de eosinófilos, subtipo histológico y estadio de la enfermedad. Las variables cuantitativas se evaluaron con las pruebas de Kolmogorow-Smirnov y se aplicó la prueba de Mann Whitney y &#967;2 para evaluar las variables cualitativas.  RESULTADOS:  Se encontraron 99 expedientes de pacientes con cáncer de ovario: 11.1% con eosinofilia vs 6% en las controles (p &lt; 0.197). Los subtipos histológicos de células germinales y epiteliales fueron los de mayor eosinofilia y el estadio III fue el de mayor asociación (n = 19).  CONCLUSIÓN: Se abre la posibilidad de diseñar un estudio fase I con el fin de identificar la asociación entre la eosinofilia y el diagnóstico de cáncer de ovario, subtipo epitelial y células germinales.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract:  OBJECTIVE: To identify the possible association between blood eosinophilia and diagnosis of ovarian cancer.  MATERIALS AND METHODS: A retrospective cross-sectional phase 1 study of diagnostic test development was performed. Data were collected on the medical records of patients who consulted at San Vicente Foundation Hospital with a diagnosis of ovarian tumor from 01/01/2011 to 01/01/2016. All patients with a diagnostic impression of ovarian tumor with at least one hemoleukogram at admission were included and those medical records of patients with a history of atopy, who were currently studying with parasitosis or with diagnosis of Hodgkin Lymphoma, colorectal cancer, breast and cervix were excluded. Age, absolute number of eosinophils, histological subtype and stage of the disease were the variables studied. The quantitative variables were evaluated with the Kolmogorov-Smirnov tests and the Mann Whitney and &#967;2 test was applied to evaluate the qualitative variables.  RESULTS:  We found 99 files of patients with ovarian cancer: 11.1% with eosinophilia vs 6% in controls (p &lt; 0.197). The histological subtypes of germinal and epithelial cells were the most eosinophilic and stage III was the most associated (n = 19).  CONCLUSION:  To design a phase I study in order to identify the association between eosinophilia and diagnosis of ovarian cancer epithelial subtype and germ cells is possible.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Eosinófilos]]></kwd>
<kwd lng="es"><![CDATA[cáncer de ovario]]></kwd>
<kwd lng="es"><![CDATA[prueba diagnóstica]]></kwd>
<kwd lng="es"><![CDATA[tumor de ovario]]></kwd>
<kwd lng="es"><![CDATA[linfoma de Hodgkin]]></kwd>
<kwd lng="es"><![CDATA[cáncer colorrectal]]></kwd>
<kwd lng="es"><![CDATA[cuello uterino]]></kwd>
<kwd lng="es"><![CDATA[diagnóstico]]></kwd>
<kwd lng="en"><![CDATA[Eosinophils]]></kwd>
<kwd lng="en"><![CDATA[Ovarian cancer]]></kwd>
<kwd lng="en"><![CDATA[Diagnostic test]]></kwd>
<kwd lng="en"><![CDATA[Ovarian tumor]]></kwd>
<kwd lng="en"><![CDATA[Hodgkin lymphoma]]></kwd>
<kwd lng="en"><![CDATA[Colorectal cancer]]></kwd>
<kwd lng="en"><![CDATA[Cervix diagnosis]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Barnholtz-Sloan]]></surname>
<given-names><![CDATA[JS]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovarian cancer: changes in patterns at diagnosis and relative survival over the last three decades]]></article-title>
<source><![CDATA[Am J Obs Gynecol]]></source>
<year>2003</year>
<volume>189</volume>
<page-range>1120</page-range></nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="">
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="">
<collab>Symptoms. Foundation for Women&#8217;s Cancer</collab>
<source><![CDATA[]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="">
<source><![CDATA[NCCN Clinical Practice Guidelines in Oncology]]></source>
<year></year>
</nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Zurawski]]></surname>
<given-names><![CDATA[VR]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Elevated serum CA 125 levels prior to diagnosis of ovarian neoplasia: relevance for early detection of ovarian cancer]]></article-title>
<source><![CDATA[Int J Cancer]]></source>
<year>1988</year>
<volume>42</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>677-80</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shah]]></surname>
<given-names><![CDATA[CA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Influence of ovarian cancer risk status on the diagnostic performance of the serum biomarkers mesothelin, HE4, and CA125]]></article-title>
<source><![CDATA[Cancer Epidemiol Biomarkers Prev]]></source>
<year>2009</year>
<volume>18</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>1365-72</page-range></nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Sakkal]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eosinophils in Cancer: Favourable or Unfavourable?]]></article-title>
<source><![CDATA[Curr Med Chem]]></source>
<year>2016</year>
<volume>23</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>650-66</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nolen]]></surname>
<given-names><![CDATA[BM]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Role of eotaxin-1 signaling in ovarian cancer]]></article-title>
<source><![CDATA[Clin Cander Res.]]></source>
<year>2009</year>
<volume>15</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>2647-56</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Van Mens]]></surname>
<given-names><![CDATA[SP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eosinofilie bij een solide tumor: ovariumsarcoom]]></article-title>
<source><![CDATA[Ned Tijdschr Geneeskd]]></source>
<year>2010</year>
<volume>154</volume>
</nlm-citation>
</ref>
</ref-list>
</back>
</article>
